PALI Projected Dividend Yield
Palisade Bio Inc ( NASDAQ : PALI )Palisade Bio is a biopharmaceutical company that develops therapeutics to protect the integrity of the intestinal barrier. Co.'s therapeutic candidate, LB1148, is an oral liquid formulation of the digestive enzyme inhibitor, tranexamic acid, used to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. LB1148 is formulated as an aqueous solution for oral (enteral) administration. The patented LB1148 formulation contains polyethylene glycol, carbohydrates, and electrolytes. The components of LB1148 are provided as dry powders for reconstitution in water prior to administration. 20 YEAR PERFORMANCE RESULTS |
PALI Dividend History Detail PALI Dividend News PALI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |